Seven Fleet Capital Management LP Purchases 878,692 Shares of Taysha Gene Therapies, Inc. $TSHA

Seven Fleet Capital Management LP increased its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 140.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,504,400 shares of the company’s stock after purchasing an additional 878,692 shares during the quarter. Taysha Gene Therapies makes up 1.6% of Seven Fleet Capital Management LP’s portfolio, making the stock its 13th biggest position. Seven Fleet Capital Management LP’s holdings in Taysha Gene Therapies were worth $9,940,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd lifted its holdings in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after buying an additional 4,607 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at $59,000. Guggenheim Capital LLC acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at $61,000. R Squared Ltd bought a new position in shares of Taysha Gene Therapies in the 1st quarter worth $50,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Taysha Gene Therapies in the 1st quarter worth $51,000. 77.70% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by company insiders.

Taysha Gene Therapies Stock Up 0.5%

NASDAQ:TSHA opened at $5.60 on Friday. The stock has a 50-day simple moving average of $6.06 and a 200 day simple moving average of $5.63. Taysha Gene Therapies, Inc. has a 52-week low of $2.71 and a 52-week high of $7.30. The company has a market cap of $1.82 billion, a PE ratio of -13.33 and a beta of 1.19. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research note on Tuesday, June 23rd. BMO Capital Markets boosted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th. Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Finally, Robert W. Baird lifted their price objective on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $12.77.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.